NeoGenomics (NASDAQ:NEO – Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.080-0.100 for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $661.7 million.
Analysts Set New Price Targets
Several brokerages have commented on NEO. Benchmark restated a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a research report on Tuesday, September 24th. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Wednesday. Finally, Stephens reiterated an “overweight” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, NeoGenomics currently has a consensus rating of “Moderate Buy” and an average target price of $19.89.
Get Our Latest Report on NeoGenomics
NeoGenomics Trading Up 3.5 %
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Read More
- Five stocks we like better than NeoGenomics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- What a Trump Win Looks Like for the Market Now and Into 2025
- What is the Dow Jones Industrial Average (DJIA)?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- With Risk Tolerance, One Size Does Not Fit All
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.